Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 15/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20041167 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6 | |
| SCHEMBL20041219 | 1.00 | FAP (0.60) | FAPCYP3A4CYP2D6 | |
| SCHEMBL21991574 | 0.93 | FAP (0.54) | FAPCYP3A4CYP2D6 | |
| SCHEMBL15189143 | 0.90 | FAP (0.58) | FAPCYP3A4CYP2D6 | |
| SCHEMBL20130404 | 0.90 | FAP (0.58) | FAPCYP3A4CYP2D6 | |
| SCHEMBL20130403 | 0.90 | FAP (0.58) | FAPCYP3A4CYP2D6 | |
| Tenofovir Alafenamide SCHEMBL3107144 | 0.89 | FAP (0.60) | FAPCYP3A4CYP2D6 | |
| Tenofovir Alafenamide SCHEMBL13155662 | 0.89 | FAP (0.60) | FAPCYP3A4CYP2D6 | |
| Tenofovir Alafenamide SCHEMBL14440384 | 0.89 | FAP (0.60) | FAPCYP3A4CYP2D6 | |
| Tenofovir Alafenamide SCHEMBL22139335 | 0.89 | FAP (0.60) | FAPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305795-B1 | TENOFOVIR MONOBENZYL ESTER PHOSPHAMIDE PRODRUG, PREPARATION METHOD AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-10233202-B2 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2019-03-19 | — | — | US | disclosed |
| US-20180127445-A1 | TENOFOVIR MONOBENZYL ESTER PHOSPHAMIDE PRODRUG, PREPARATION METHOD AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127445-A1 | TENOFOVIR MONOBENZYL ESTER PHOSPHAMIDE PRODRUG, PREPARATION METHOD AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3305795-A1 | TENOFOVIR MONOBENZYL ESTER PHOSPHAMIDE PRODRUG, PREPARATION METHOD AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127445-A1 | TENOFOVIR MONOBENZYL ESTER PHOSPHAMIDE PRODRUG, PREPARATION METHOD AND USE THEREOF | PNP, SLC10A1, TYMP | FAP 504/4885CYP3A4 115/4885CYP2D6 140/4885 |
| US-10233202-B2 | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | PNP, SLC10A1, TYMP | FAP 504/4885CYP3A4 115/4885CYP2D6 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.